Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on: December 21,2023

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on:December 21,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on: November 07,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on:November 07,2023

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on: December 18,2023

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on:December 18,2023

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in

Updated on: October 15,2023

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in

Updated on:October 15,2023

Oral paclitaxel yields better outcomes than intravenous paclitaxel for metastatic breast cancer

byAmerican Association for Cancer ResearchCredit: CC0 Public DomainMetastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better response and

Updated on: December 22,2023

Oral paclitaxel yields better outcomes than intravenous paclitaxel for metastatic breast cancer

byAmerican Association for Cancer ResearchCredit: CC0 Public DomainMetastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better response and

Updated on:December 22,2023

Measuring 'quality of life' is an important trend in cancer care

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainAs novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along wit

Updated on: August 27,2024

Measuring 'quality of life' is an important trend in cancer care

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainAs novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along wit

Updated on:August 27,2024

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on: December 27,2023

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on:December 27,2023

Localizing BRCA gene mutations to better treat ovarian cancer

byUniversity of GenevaDistribution of mutations in BRCA1 and BRCA2. A. Graphical summary of BRCA1 and BRCA2 mutations. Mutation plot was generated using cBioPortal MutationMapper tool. Black = n

Updated on: December 20,2023

Localizing BRCA gene mutations to better treat ovarian cancer

byUniversity of GenevaDistribution of mutations in BRCA1 and BRCA2. A. Graphical summary of BRCA1 and BRCA2 mutations. Mutation plot was generated using cBioPortal MutationMapper tool. Black = n

Updated on:December 20,2023

How employers can help cancer survivors return to work

by Stephen Bevan,The ConversationCredit: AI-generated imageWhen I lost a relative to cancer in the late 1970s, people usually viewed a cancer diagnosis with horror. At the time, many treatments

Updated on: December 20,2023

How employers can help cancer survivors return to work

by Stephen Bevan,The ConversationCredit: AI-generated imageWhen I lost a relative to cancer in the late 1970s, people usually viewed a cancer diagnosis with horror. At the time, many treatments

Updated on:December 20,2023

Sweden sees skin cancer decline in under-50s for 1st time: Study

Credit: Anna Tarazevich from PexelsSkin cancer is declining among younger adults in Sweden for the first time after decades of increases, making it the first European country to see a fall, researcher

Updated on: September 27,2024

Sweden sees skin cancer decline in under-50s for 1st time: Study

Credit: Anna Tarazevich from PexelsSkin cancer is declining among younger adults in Sweden for the first time after decades of increases, making it the first European country to see a fall, researcher

Updated on:September 27,2024

New blood test revolutionizes early cancer detection in Li-Fraumeni Syndrome patients

In a study published inCancer Discovery, researchers from Canada tested the use of a multimodal liquid biopsy assay based on cell-free DNA (cfDNA) for early cancer detection in patients with Li-

Updated on: October 30,2023

New blood test revolutionizes early cancer detection in Li-Fraumeni Syndrome patients

In a study published inCancer Discovery, researchers from Canada tested the use of a multimodal liquid biopsy assay based on cell-free DNA (cfDNA) for early cancer detection in patients with Li-

Updated on:October 30,2023

Scientists find powerhouses that fight tumours from within

In recent years doctors have turned to a new treatment for cancer, immunotherapy, which works by leveraging the body's own immune system to fight tumoursLurking deep inside some tumours are "

Updated on: December 20,2023

Scientists find powerhouses that fight tumours from within

In recent years doctors have turned to a new treatment for cancer, immunotherapy, which works by leveraging the body's own immune system to fight tumoursLurking deep inside some tumours are "

Updated on:December 20,2023